VXRT
Vaxart, Inc. NASDAQ Listed Dec 11, 1981$0.58
Mkt Cap $140.4M
52w Low $0.31
50.9% of range
52w High $0.84
50d MA $0.56
200d MA $0.56
P/E (TTM)
3.6x
EV/EBITDA
1.3x
P/B
1.5x
Debt/Equity
0.1x
ROE
18.6%
P/FCF
17.5x
RSI (14)
60.70
ATR (14)
$0.06
Beta
1.32
50d MA
$0.56
200d MA
$0.56
Avg Volume
318.8K
Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine, which is in Phase II clinical trial for the treatment of SARS-CoV-2 infection. It is also developing therapeutic vaccines for cervical cancer and dysplasia caused by human papillomavirus. The company is headquartered in South San Francisco, California.
170 Harbor Way · South San Francisco, CA 94080 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug 6, 2026 | AMC | -0.12 | -0.06 | +50.0% | 0.57 | -1.8% | -4.3% | +4.5% | — | — | — | — |
| May 7, 2026 | AMC | 0.02 | 0.02 | +0.0% | 0.74 | -0.7% | -5.4% | -7.1% | +4.6% | +1.5% | -5.8% | — |
| Mar 12, 2026 | AMC | -0.08 | 0.24 | +400.0% | 0.74 | -1.4% | -14.9% | +7.9% | +0.0% | -7.4% | +3.2% | — |
| Nov 13, 2025 | AMC | -0.07 | -0.04 | +42.9% | 0.37 | +0.0% | +10.8% | -4.9% | +0.0% | +0.0% | -2.6% | — |
| Aug 13, 2025 | AMC | -0.09 | -0.07 | +22.2% | 0.37 | -2.7% | -2.7% | +2.8% | -2.7% | +2.8% | -2.7% | — |
| May 13, 2025 | AMC | -0.07 | -0.07 | +0.0% | 0.42 | -0.1% | -3.7% | +6.1% | +19.0% | -1.0% | +1.6% | — |
| Mar 20, 2025 | AMC | -0.10 | -0.05 | +50.0% | 0.57 | -4.9% | -9.1% | -0.7% | -6.1% | -3.5% | -1.6% | — |
| Nov 13, 2024 | AMC | -0.10 | -0.06 | +40.0% | 0.71 | -3.8% | -11.8% | -7.9% | +5.2% | +1.6% | -2.0% | — |
| Aug 8, 2024 | AMC | -0.03 | -0.09 | -237.3% | 0.63 | -1.6% | -8.0% | +0.8% | +2.7% | -1.4% | +25.7% | — |
| May 13, 2024 | AMC | -0.16 | -0.14 | +12.5% | 0.82 | +9.6% | +5.5% | +9.2% | +8.0% | -6.0% | -6.5% | — |
| Mar 14, 2024 | AMC | -0.15 | -0.12 | +20.0% | 1.10 | +0.9% | -1.8% | +7.4% | +0.0% | +6.9% | -0.8% | — |
| Nov 2, 2023 | AMC | -0.18 | -0.11 | +38.9% | 0.67 | -3.7% | +5.1% | +2.1% | +2.2% | +3.8% | -3.7% | — |
| Aug 3, 2023 | AMC | -0.19 | -0.16 | +15.8% | 0.75 | +0.0% | +2.7% | -6.5% | +1.4% | +1.4% | -4.1% | — |
| May 4, 2023 | AMC | -0.19 | -0.19 | +0.0% | 0.86 | -7.0% | +1.2% | -1.1% | +1.2% | +16.1% | +3.0% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 27 | B. Riley Securities | Maintains | Buy → Buy | — | $0.46 | $0.46 | -1.0% | -1.6% | -7.8% | -3.4% | -8.5% | -6.0% |
| Jan 31 | B. Riley Securities | Upgrade | Neutral → Buy | — | $0.98 | $1.02 | +4.1% | +20.4% | +1.7% | +0.0% | -2.5% | +2.6% |
| Sep 7 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $0.80 | $0.79 | -1.2% | -8.0% | +5.8% | +1.2% | -2.3% | -1.3% |
| Aug 7 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $0.77 | $0.76 | -1.3% | -6.5% | +1.4% | +1.4% | -4.1% | -2.8% |
| Dec 19 | B. Riley Securities | Maintains | Neutral → Neutral | — | $1.06 | $1.03 | -2.8% | -14.2% | +1.1% | +0.0% | -2.2% | -7.8% |
| Sep 2 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $3.15 | $3.08 | -2.2% | -9.5% | -3.9% | +3.3% | +1.1% | +0.3% |
| May 19 | B. Riley Securities | Maintains | Neutral → Neutral | — | $3.16 | $3.11 | -1.6% | +11.4% | +5.7% | -9.4% | -3.9% | +3.1% |
| Jun 30 | B. Riley Securities | Downgrade | Buy → Neutral | — | $8.25 | $8.10 | -1.8% | -9.2% | +2.5% | -2.6% | -1.6% | -3.8% |
| Aug 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.75 | $10.56 | -1.8% | -14.4% | -1.2% | +0.6% | +11.3% | -6.5% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| May 22, 2026 | Watson W. MarkDir | — | Buy | 10,000 | $0.65 | $7K | 134,125 | +1.59% | -3.97% |
8-K · 8.01
!! High
Vaxart, Inc. -- 8-K 8.01: Material Event / Announcement
Jul 28
8-K · 7.01
! Medium
Vaxart, Inc. -- 8-K 7.01: Regulation FD Disclosure
Jul 17
8-K · 8.01
!! High
Vaxart, Inc. -- 8-K 8.01: Material Event / Announcement
Jul 7
8-K · 1.01
!! High
Vaxart, Inc. -- 8-K 1.01: Material Agreement
Jul 2
8-K · 1.01
!! High
Vaxart, Inc. -- 8-K 1.01: Material Agreement
Jun 26
8-K · 8.01
!! High
Vaxart, Inc. -- 8-K 8.01: Material Event / Announcement
Vaxart faces a proxy contest as shareholders have nominated three dissident director candidates for the upcoming Annual Meeting, prompting management to communicate directly with investors about the board election.
May 19
8-K · 5.02
!!! Very High
Vaxart, Inc. -- 8-K 5.02: Executive Change
Vaxart appoints James B. Breitmeyer as Chief Executive Officer, signaling leadership transition that investors should monitor for strategic direction and operational changes.
Apr 23
8-K · 8.01
!! High
Vaxart, Inc. -- 8-K 8.01: Material Event / Announcement
Vaxart expanded its leased office space with a 36-month agreement while simultaneously terminating its Harbor Way lease, indicating operational consolidation and potential cost management efforts.
Apr 21
8-K · 1.01
!! High
Vaxart, Inc. -- 8-K 1.01: Material Agreement
Vaxart secured a $25 million financing agreement with Lincoln Park Capital Fund, providing liquidity for operations and potentially signaling investor confidence in the vaccine developer's pipeline.
Apr 17
8-K
Unknown — 8-K Filing
A scheduled March 2026 investor fireside chat signals management is preparing to address shareholder questions, likely about pipeline progress or strategic direction, giving investors a rare opportunity for real-time insights.
Mar 12
Institutional (13F) — Top 2
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Heritage Wealth Advisors | 29,655 | $18K | Added | Mar 2026 |
| 2 | Lvm Capital Management Ltd/mi | 25,000 | $15K | — | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 1
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | Guggenheim Active Allocation Fund | 715 | $568 | Feb 2026 |
Valuation
Market Cap
$140.4M
Enterprise Value
$74.6M
P/E (TTM)
3.64x
Forward P/E
—
PEG Ratio
-0.03x
P/B
1.51x
P/S
0.58x
P/FCF
17.50x
EV/EBITDA
1.26x
Shares Out
230.3M
Financials (TTM)
Revenue
$243.1M
Net Income
$38.6M
EBITDA
$59.4M
Free Cash Flow
$7.6M
Op Cash Flow
$7.7M
EPS Basic
$0.07
EPS Diluted
$0.15
EPS Forward
$-0.38
Gross Margin
88.8%
Op Margin
21.7%
Net Margin
15.9%
Balance Sheet
Total Assets
$186.1M
Total Liab.
$98.3M
Total Equity
$87.8M
Cash
$63.8M
LT Debt
$6.0M
Book Value/Sh
$0.38
Debt/Equity
0.10x
Current Ratio
5.34
Quick Ratio
5.34
Returns & Growth
ROE
18.6%
ROA
8.8%
ROIC
13.5%
Rev Growth YoY
+726.7%
EPS Growth YoY
+150.0%
Price Returns
2W
+27.7%
1M
+6.2%
3M
-10.8%
6M
+1.8%
12M
+56.8%
Technicals
52W High
$0.84
52W Low
$0.31
50d MA
$0.56
200d MA
$0.56
RSI (14)
60.70
ATR (14)
$0.06
Beta
1.32
Avg Volume
319K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$2.00
High
$2.00
Low
$2.00
Median
$2.00
Data updated apr 27, 2026 10:03pm
· Source: financialmodelingprep.com